1. Home
  2. TRAK vs IPHA Comparison

TRAK vs IPHA Comparison

Compare TRAK & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAK

ReposiTrak Inc.

HOLD

Current Price

$8.64

Market Cap

157.2M

Sector

Technology

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.74

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRAK
IPHA
Founded
1990
1999
Country
United States
France
Employees
N/A
163
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.2M
165.3M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
TRAK
IPHA
Price
$8.64
$1.74
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
51.4K
4.8K
Earning Date
05-14-2026
03-26-2026
Dividend Yield
0.90%
N/A
EPS Growth
20.69
N/A
EPS
0.28
N/A
Revenue
$21,007,076.00
N/A
Revenue This Year
$6.61
$180.36
Revenue Next Year
$10.04
N/A
P/E Ratio
$30.86
N/A
Revenue Growth
4.84
N/A
52 Week Low
$6.94
$1.18
52 Week High
$18.05
$2.62

Technical Indicators

Market Signals
Indicator
TRAK
IPHA
Relative Strength Index (RSI) 48.88 53.81
Support Level $8.78 $1.73
Resistance Level $9.09 $1.93
Average True Range (ATR) 0.33 0.06
MACD 0.02 -0.00
Stochastic Oscillator 74.82 60.84

Price Performance

Historical Comparison
TRAK
IPHA

About TRAK ReposiTrak Inc.

ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: